AURKB and small cell lung carcinoma: The MTD/RP2D was investigated in the expansion phase of this study (to be published separately) in patients with previously treated SCLC (both limited-stage [LS] and extensive-stage [ES]), whose tumours are expected to be sensitive to AURKB inhibition due to the characteristic rapid proliferation and reliance on accelerated mitosis of SCLC.